Petros Pharmaceuticals, Inc. (PTPI:OTC) closed at $0.003 on October 23, 2026, up 25.00% on the day. The stock trades 89.6% below its 52-week high of $0.024 and 25.0% above its 52-week low of $0.002. Petros Pharmaceuticals, Inc. is part of the Health Care sector.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Prescription Medications segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.
Find more stocks like PTPI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.